Guggenheim Cuts Inventiva (NASDAQ:IVA) Price Target to $9.00

Inventiva (NASDAQ:IVA - Get Free Report) had its price target cut by investment analysts at Guggenheim from $12.00 to $9.00 in a report issued on Friday,Benzinga reports. The firm presently has a "buy" rating on the stock. Guggenheim's price target indicates a potential upside of 189.39% from the stock's current price.

Several other brokerages have also recently commented on IVA. TD Cowen initiated coverage on shares of Inventiva in a research report on Friday, February 21st. They issued a "buy" rating and a $10.00 price target for the company. HC Wainwright reiterated a "buy" rating and issued a $13.00 price objective on shares of Inventiva in a research note on Friday, March 28th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, Inventiva presently has an average rating of "Moderate Buy" and a consensus price target of $10.40.

Inventiva Stock Up 2.3 %

NASDAQ IVA traded up $0.07 on Friday, reaching $3.11. The stock had a trading volume of 7,472 shares, compared to its average volume of 62,291. The stock has a fifty day moving average price of $2.82 and a two-hundred day moving average price of $2.53. Inventiva has a 12-month low of $1.53 and a 12-month high of $3.98.

About Inventiva

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.